Last Updated: 2026-03-24 PT | Kind: gap-analysis
The differential diagnosis of 4R tauopathies—progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease (AGD)—remains a significant clinical challenge. Unlike Alzheimer's disease (AD), which features mixed 3R+4R tau pathology, the pure 4R tauopathies require distinct biomarker approaches for ante-mortem diagnosis. This page summarizes current biomarker strategies for distinguishing between 3R, 3R+4R, and 4R tauopathies.
Tau protein exists as six isoforms in the human brain, resulting from alternative splicing of the MAPT gene:
| Tauopathy | Primary Isoform | Key Pathological Features |
|---|---|---|
| Alzheimer's Disease | 3R+4R | Amyloid plaques, neurofibrillary tangles |
| Progressive Supranuclear Palsy | 4R | Globose tangles, tufted astrocytes |
| Corticobasal Degeneration | 4R | Astrocytic plaques, ballooned neurons |
| Pick's Disease | 3R | Pick bodies, ballooned neurons |
| Argyrophilic Grain Disease | 4R | Argyrophilic grains, coiled bodies |
CSF analysis remains the most accessible approach for tau isoform discrimination:
Recent advances in ultra-sensitive assays enable blood biomarker detection:
| Biomarker | AD | PSP | CBD | Utility |
|---|---|---|---|---|
| p-tau181 (CSF) | +++ | + | + | AD vs. 4R |
| p-tau217 (CSF) | +++ | + | + | AD vs. 4R |
| p-tau181 (blood) | +++ | ++ | ++ | Screening |
| NfL (blood) | ++ | +++ | +++ | Disease progression |
| Ligand | Target | Status | Utility |
|---|---|---|---|
| Flortaucipir (FTP) | AD tau (3R+4R) | FDA approved | AD-specific |
| MK-6240 | AD tau (3R+4R) | Investigational | AD-specific |
| PI-2620 | 4R tau | Investigational | PSP, CBD |
| APN-1607 | 4R tau | Investigational | PSP, CBD |
RT-QuIC (Real-Time Quaking-Induced Conversion) and related technologies show promise for detecting disease-specific tau aggregates:
Emerging assays target specific tau phosphorylation patterns and conformations:
Biomarker stratification is essential for:
Several trials are incorporating biomarker endpoints:
Hall, B. et al. CSF p-tau181 distinguishes 4R tauopathies from Alzheimer's disease. Neurology. 2022. ↩︎
Janelidze, S. et al. CSF p-tau217 outperforms p-tau181 and t-tau for Alzheimer's disease diagnosis. EMBO Molecular Medicine. 2023. ↩︎
Mattsson-Carlgren, N. et al. p-tau231 as a biomarker for early Alzheimer's disease. Alzheimer's & Dementia. 2024. ↩︎
Keshavan, A. et al. Blood phosphorylated tau181 as a biomarker for neurodegenerative disease. Nature Aging. 2021. ↩︎
Palmqvist, S. et al. Discriminative accuracy of plasma p-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020. ↩︎
Khalil, M. et al. Neurofilament light chain as a biomarker in neurological disorders. Nature Reviews Neurology. 2018. ↩︎
Okamura, N. et al. Tau PET imaging: past, present, and future. Journal of Neurology, Neurosurgery & Psychiatry. 2022. ↩︎
Saijo, E. et al. RT-QuIC detection of tau aggregates in neurodegenerative diseases. Acta Neuropathologica. 2023. ↩︎